Late Breaker D WELBD1
Please enter your email :
Type:
Oral Abstract Session Back
Venue: Session Room 3
Time: 16:30 - 17:30, 22.07.2009
Code: WELBD1
Chairs: Sten H. Vermund, United States
Glenda Gray, South Africa
Session recording provided by International AIDS Society



Presentations in this session:

16:30
WELBD101
Abstract
Powerpoint		Evaluation of PMTCT coverage in four African countries: The PEARL Study
Presented by David Coetzee, South Africa
D. Coetzee1, E.M. Stringer2, B.H. Chi2, N. Chintu2, T.L. Creek3, D.K. Ekouevi4, K. Stinson1, P. Tih5, T. Welty5, F. Dabis6, N. Shaffer3, C.M. Wilfert7, J.S.A. Stringer2
1Infectious Disease Epidemiology Unit, University of Cape Town, Cape Town, South Africa, 2University of Alabama at Birmingham, Centre for Infectious Disease Research in Zambia, Lusaka, Zambia, 3Centers for Disease Control and Prevention, Global AIDS Program, Atlanta, United States, 4PAC-CI Programme, Abijan, Cote D'Ivoire, 5Cameroon Baptist Convention Health Board, Nso, Cameroon, 6Institut de Santé Publique Épidémiologie Développement, Université Victor Segalen, Bordeaux, France, 7Elizabeth Glaser AIDS FoundationPediatric AIDS Foundation, Chapel Hill, United States

16:40
WELBD102
Abstract
Powerpoint		A strategy of early antiretroviral therapy for patients with acute opportunistic infections: a cost-effectiveness analysis of ACTG 5164
Presented by Paul Sax, United States
P. Sax1,2, C. Sloan3, B. Schackman4, P. Grant5, J. Rong6, A. Zolopa5, E. Losina1,6,7, K. Freedberg6,7
1Brigham and Women's Hospital, Boston, United States, 2Harvard Medical School, Boston, United States, 3Massachusetts General Hospital, Boston, United States, 4Weill Cornell Medical College, New York, United States, 5Stanford University School of Medecine, Palo Alto, United States, 6Boston University School of Public Health, Boston, United States, 7Massachusetts General Hospital / Harvard Medical School, Boston, United States

16:50
WELBD103
Abstract
Powerpoint		Cost-effectiveness of preventing loss to follow-up in HIV treatment programs: a Côte d'Ivoire appraisal
Presented by Kenneth Freedberg, United States
E. Losina1,2,3, H. Touré4, L. Uhler2, X. Anglaret4, A.D. Paltiel5, E. Balestre4, R. Walensky2,6,7, E. Messou8, M. Weinstein7, F. Dabis4, K. Freedberg2,3,6,7, ART-LINC of IeDEA Collaboration and CEPAC International investigators
1Brigham and Women's Hospital, Boston, United States, 2Massachusetts General Hospital, Boston, United States, 3Boston University School of Public Health, Boston, United States, 4Université Victor Segalen, Bordeaux, France, 5Yale University, New Haven, United States, 6Harvard Medical School, Boston, United States, 7Harvard School of Public Health, Boston, United States, 8CePReF, Abidjan, Cote D'Ivoire

17:00
WELBD104
Abstract
Powerpoint		Poor immunological response and high mortality in HIV-infected patients older than 50 years receiving antiretroviral treatment in West Africa: The IeDEA WestAfrica collaboration
Presented by Didier Koumavi Ekouevi, Cote D'Ivoire
A. Lokossoue1,2, S.-P. Eholie1, M. Maiga3, E. Messou4, D.M. Zannou5, A. Minga6, E. Bissagnene1, P.S. Sow7, F. Dabis2, D.K. Ekouevi2,8, IeDEA West Africa Collaboration
1Service de Maladies Infectieuses et Tropicales (SMIT), CHU de Treichville, Abidjan, Cote D'Ivoire, 2ISPED, HIV Africa team, Bordeaux, France, 3Service d'Hépato-Gastro-Entérologie, Hôpital Gabriel Touré, Bamako, Mali, 4ACONDA - CePReF, Abidjan, Cote D'Ivoire, 5Service de Médecine Interne, CHU Hubert Maga, Cotonou, Benin, 6Centre National de Transfusion Sanguine (CNTS), Abidjan, Cote D'Ivoire, 7SMIT, CHU de Fann, Dakar, Senegal, 8Programme PAC-CI, IeDEA-West Africa, Abidjan, Cote D'Ivoire

17:10
WELBD105
Abstract
Powerpoint		Scaling up access to antiretroviral therapy (ART) in low- and middle-income countries: global and regional progress in 2008
Presented by Yves Souteyrand, Switzerland
Y. Souteyrand1, P. Akwara2, M. Warner Smith3, M. Beusenberg1, M. Jashi2, C. Hayashi1, R. Ekpini2, P. Baijal1, R. Gass2, C. Luo2, T. Guerma1
1World Health Organization (WHO), HIV/AIDS, Geneva, Switzerland, 2UNICEF, New York, United States, 3UNAIDS, Monitoring and Evaluation Division, Geneva, Switzerland

Powerpoints presentations
Evaluation of PMTCT coverage in four African countries: The PEARL Study - Coetzee

A strategy of early antiretroviral therapy for patients with acute opportunistic infections: a cost-effectiveness analysis of ACTG 5164 - Sax

Cost-effectiveness of preventing loss to follow-up in HIV treatment programs: a Côte d'Ivoire appraisal - Freedberg

Poor immunological response and high mortality in HIV-infected patients older than 50 years receiving antiretroviral treatment in West Africa: The IeDEA WestAfrica collaboration - Ekouevi

Scaling up access to antiretroviral therapy (ART) in low- and middle-income countries: global and regional progress in 2008 - Souteyrand



Rapporteur report

Track D report by Jason Reed


 

 

This session covered late breaker operations research presentations

The second presentation used a model (CEPAC) to project cost-effectiveness of delivering ART within 2 weeks of diagnosis vs. deferring ART for one month longer among patients whose presentation to care was with an OI.  The model used input data from ACTG 5164 in the United States.  Early ART implementation in patients presenting with an acute OI would be cost effective, though ACTG did not enroll patients with TB or critical illness, so the model cannot account for either.  If efficacy of first line therapy were reduced, early ART would not be cost effective.

The third presentation addressed the problem of loss to follow-up and suggested that preventing LTFU may be a better approach than finding those after becoming ‘lost’.  The investigators developed a model that projected life expectancy with and without LTFU at one year in Cote d’Ivoire.  Based upon a theoretical intervention of four activities—elimination of ART copayments, free OI medications, healthcare worker training, transportation—cost effectiveness was modeled to demonstrate that prevention of LTFU would be cost effective if programs were at least moderately successful.

The fourth presentation examined different clinical outcomes for those younger and older than 50 to demonstrate age as an independent predictor of immunologic failure as well as death.  Poorer clinical outcomes among those over 50 may have a number of possible causes. 

The last presentation by Dr. Souteyrand was not operational research.

 


   

   

    The organizers reserve the right to amend the programme.
Contact Us | Site map © 2009 International AIDS Society